LFST

AI MemoPost-earnings T+3

Lifestance Health Group

As of 2026-08-08/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Confirmed Q2 results and raised FY 2026 outlook • 2026-11-06

Base target: $13 / p=55% prob

Biggest risk

The setup remains execution-sensitive: growth depends on clinician recruitment, productivity, visit volumes, and revenue per visit. Net long-term debt of $259.0 million exceeded cash of $225.9 million at quarter-end, while recent insider open-market sales add a sentiment overhang. [#SEC-8K-2026-08-06] [#SEC-FORM4-2026-06-30]

Invalidation

Break below $9 or thesis failure.

What would change my mind?

The August 6 8-K showed accelerating scale economics: revenue grew 26%, Center Margin grew 41%, Adjusted EBITDA grew 94%, and management raised FY 2026 guidance versus the ranges disclosed with Q1 results. Continued clinician additions, visit growth, productivity, and operating leverage could support re-rating. [#SEC-8K-2026-08-06] [#SEC-8K-2026-05-07]

Research note

Recommendation

—

Confidence

high

As of

2026-08-08

Base target

$13

p=55%

Bull target

$15

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings follow-through and valuation risk
Clinician and visit-volume operating leverage
The August 6 8-K showed accelerating scale economics: revenue grew 26%, Center Margin grew 41%, Adjusted EBITDA grew 94%, and management raised FY 2026 guidance versus the ranges disclosed with Q1 results.

BearKey bullets

High valuation leaves limited tolerance for slower clinician growth, visit volumes, revenue per visit, or margin expansion.
Net long-term debt exceeded cash at the end of Q2, constraining financial flexibility.
No consensus earnings surprise data, post-earnings analyst target changes, estimate revisions, or detailed market-reaction attribution are available.

WatchKey bullets

Confirmed Q2 results and raised FY 2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $13 (p=55%)

Target spread vs base: +14% / -31%

Scenario probabilities

Bull Target: $15 (p=25%)Base Target: $13 (p=55%)Bear Target: $9 (p=20%)

Commentary

News tone is positive following the confirmed company earnings release, raised FY outlook, and repurchase announcement. The anchor price was $10.84 on August 7, and the latest quote was modestly higher, but no trusted source attributes the move to results, guidance, or commentary. Post-print analyst revisions are unavailable, so confidence remains tentative and monitoring-oriented.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings follow-through and valuation risk
Clinician and visit-volume operating leverage

Scenarios

Bull Target (Scenario probability)

$15 / p=25% prob

Base Target (Scenario probability)

$13 / p=55% prob

Bear Target (Scenario probability)

$9 / p=20% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-06
Confirmed Q2 results and raised FY 2026 outlook
LifeStance's August 6, 2026 Form 8-K exhibit reported Q2 revenue of $435.4 million, up 26%, Adjusted EBITDA of $66.0 million, up 94%, raised full-year revenue and EBITDA ranges, and announced a $100 million repurchase program. [#SEC-8K-2026-08-06]
Prob 80.00% • Move 8.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Post-earnings follow-through and valuation risk
2026-11-06
The latest quote was $10.84, up 1.5% from the prior close, but post-print analyst revisions and market-attribution data remain unavailable. A high valuation could amplify downside if growth or margin momentum moderates.
Prob 35% • Move -6% • Priced-in 40%

Long-term Catalysts

Months to a year

Clinician and visit-volume operating leverage
2027-08-08
Clinicians increased 11% to 8,542 and visits increased 19% to 2.6 million, supporting higher revenue per visit, margin expansion, and stronger cash generation. [#SEC-8K-2026-08-06]
Prob 65% • Move 12% • Priced-in 55%

Risks

High valuation leaves limited tolerance for slower clinician growth, visit volumes, revenue per visit, or margin expansion.
Net long-term debt exceeded cash at the end of Q2, constraining financial flexibility.
No consensus earnings surprise data, post-earnings analyst target changes, estimate revisions, or detailed market-reaction attribution are available.
Peer comparisons are broad and not sufficiently direct for strong relative-valuation conclusions.
Recent director and 10% owner open-market sales may weigh on sentiment, though they are not operating evidence. [#SEC-FORM4-2026-06-30] [#SEC-FORM4-2026-05-14]

Peers

Symbol	Summary
IRTC	Same-sector, similar-market-cap candidate, but cardiac-rhythm medical-device exposure is not a close operating match.
CON	Similar-market-cap health-care candidate, but occupational-health services make it a loose comparison.
BLLN	Similar-market-cap health-care candidate; business-model comparability is limited.
ABT	Large diversified health-care and medtech reference point, not a direct peer.
BSX	Large diversified medical-device reference point, with limited direct comparability.
EW	Large medtech reference point; useful only for broad sector context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

IRTC

Same-sector, similar-market-cap candidate, but cardiac-rhythm medical-device exposure is not a close operating match.

CON

Similar-market-cap health-care candidate, but occupational-health services make it a loose comparison.

BLLN

Similar-market-cap health-care candidate; business-model comparability is limited.

ABT

Large diversified health-care and medtech reference point, not a direct peer.

BSX

Large diversified medical-device reference point, with limited direct comparability.

Large medtech reference point; useful only for broad sector context.